New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature

Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found in patients with vitiligo, which explains the reasons for the use of anti-TNFa agents and IL-17 inhibitors to treat this condition [9], but no clinical response was obtained. [...]we describe two new cases of de novo vitiligo (of only three cases published in the literature) during anti-IL17 treatment in two psoriatic patients during secukinumab treatment.